trending Market Intelligence /marketintelligence/en/news-insights/trending/0f5S-CgG13rwIb3DhePepg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US FDA approves Bristol-Myers' Opdivo to treat bladder cancer

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


US FDA approves Bristol-Myers' Opdivo to treat bladder cancer

Bristol-Myers Squibb Co. received U.S. FDA approval for Opdivo as an intravenous treatment for a type of bladder cancer.

The drug will be used to treat patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with such chemotherapy.